PRDX4 and silicosis: In vivo studies in a silicosis mouse model demonstrated that pharmacological inhibition of PRDX4 using conoidin A (Con A) significantly improved lung function, reduced fibrosis and inflammatory infiltration, and decreased collagen deposition and lung damage [111].